North Carolina hospital warns patients after phishing attack

The Catawba Valley Medical Center—a North Carolina-based hospital—is issuing notices to patients following a phishing attack that accessed several employee email accounts.

According to the notice, investigators determined the phishing attack happened between July 4 and Aug. 17, 2018. During the attack, hackers were able to gain access to three employee email accounts—possibly exposing some patient information, like names, birth dates, health information, services received at the hospital, health insurance information and some Social Security numbers.

The hospital stated there’s no evidence that any patient information has been misused and encouraged patients to review their information with their health insurer. The hospital is also mailing notices to affected patients and has created a call center to answer any questions about the security incident.

“We deeply regret any inconvenience or concern this incident may cause our patients,” the hospital said in a statement. “To help prevent something like this from happening in the future, we have hired security experts to enhance our employee education; we have implemented tighter e-mail controls; and we continue to upgrade our hardware and software platforms to combat these malicious threats.”

""

Danielle covers Clinical Innovation & Technology as a senior news writer for TriMed Media. Previously, she worked as a news reporter in northeast Missouri and earned a journalism degree from the University of Illinois at Urbana-Champaign. She's also a huge fan of the Chicago Cubs, Bears and Bulls. 

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.